Abstract
Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace. Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.
| Original language | English (US) |
|---|---|
| Journal | Cell Stem Cell |
| DOIs | |
| State | Accepted/In press - 2016 |
Fingerprint
ASJC Scopus subject areas
- Cell Biology
- Molecular Medicine
- Genetics
Cite this
Selling Stem Cells in the USA : Assessing the Direct-to-Consumer Industry. / Turner, Leigh; Knoepfler, Paul S.
In: Cell Stem Cell, 2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Selling Stem Cells in the USA
T2 - Assessing the Direct-to-Consumer Industry
AU - Turner, Leigh
AU - Knoepfler, Paul S
PY - 2016
Y1 - 2016
N2 - Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace. Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.
AB - Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace. Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.
UR - http://www.scopus.com/inward/record.url?scp=84978493321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978493321&partnerID=8YFLogxK
U2 - 10.1016/j.stem.2016.06.007
DO - 10.1016/j.stem.2016.06.007
M3 - Article
C2 - 27374789
AN - SCOPUS:84978493321
JO - Cell Stem Cell
JF - Cell Stem Cell
SN - 1934-5909
ER -